Invasive pneumococcal disease.
National Institute of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Mpapudesu@aol.com
B
B
Papudesu
M
M
Menon
N
N
Yunis
S
S
Kottilil
D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001769:Blood / Q000382:microbiology; D002439:Cefotaxime / Q000008:administration & dosage; D002511:Cephalosporins / Q000008:administration & dosage; D002555:Cerebrospinal Fluid / Q000382:microbiology; D003937:Diagnosis, Differential; D017548:Echocardiography, Transesophageal; D004917:Erythromycin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D010406:Penicillins / Q000008:administration & dosage; D011008:Pneumococcal Infections / Q000175:diagnosis / Q000188:drug therapy; D013902:Radiography, Thoracic; D013296:Streptococcus pneumoniae / Q000302:isolation & purification; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D014640:Vancomycin / Q000008:administration & dosage
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D010406:Penicillins; D004917:Erythromycin; D014640:Vancomycin; D002439:Cefotaxime